These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 4022211)

  • 21. Uremic middle molecules exist and are biologically active.
    Bergström J; Fürst P; Zimmerman L
    Clin Nephrol; 1979 May; 11(5):229-38. PubMed ID: 455821
    [No Abstract]   [Full Text] [Related]  

  • 22. In vivo accumulation of sodium pump inhibitor by normal and uremic erythrocytes.
    Gallice P; Lai E; Brunet P; Berland Y; Elsen R; Crevat A
    Int J Artif Organs; 1993 Mar; 16(3):120-2. PubMed ID: 8390969
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Whole blood platelet aggregation in uremic dogs.
    Forsythe LT; Jackson ML; Meric SM
    Am J Vet Res; 1989 Oct; 50(10):1754-7. PubMed ID: 2802308
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Inhibitory mechanism of platelet energy production and platelet functions by PGE1 and uremic toxins (author's transl)].
    Kuramoto A
    Nihon Ketsueki Gakkai Zasshi; 1973 Aug; 36(4):477-87. PubMed ID: 4799441
    [No Abstract]   [Full Text] [Related]  

  • 25. Energy production and utilization by human platelets in the presence of some guanidines and phenols (uremic toxins) that inhibit aggregation.
    Carroll HJ
    Thromb Diath Haemorrh; 1975 Sep; 34(1):63-71. PubMed ID: 1188836
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Chemical analytic approaches to the definition of uremic toxins.
    Furst P; Bergstrom J; Gordon A; Zimmermann L
    Ateneo Parmense Acta Biomed; 1975; 46(5):307-16. PubMed ID: 1232992
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Methodology for identification of serum middle molecules.
    Buzio C; Montagna G; Calderini C; Manari A; Migone L
    Artif Organs; 1981; 4 Suppl():22-7. PubMed ID: 7295090
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Evaluation of acquired platelet dysfunctions in uremic and cirrhotic patients using the platelet function analyzer (PFA-100 ): influence of hematocrit elevation.
    Escolar G; Cases A; Viñas M; Pino M; Calls J; Cirera I; Ordinas A
    Haematologica; 1999 Jul; 84(7):614-9. PubMed ID: 10406903
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Hemoperfusion with uncoated amberlite XE-336 resin in normal and uremic dogs.
    Rosenbaum JL; Kramer MS; Raja R
    Nephron; 1978; 21(1):27-37. PubMed ID: 662054
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Uremic middle molecules: analytical study of middle molecular weight fractions subpeak b4-2.
    Le Moel G; Strecker G; Cueille G; Boudet J; Man NK; Galli A; Agneray J
    Artif Organs; 1981; 4 Suppl():17-21. PubMed ID: 7295087
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Platelets and platelet function in patients with chronic uremia on maintenance hemodialysis.
    Jørgensen KA; Ingeberg S
    Nephron; 1979; 23(5):233-6. PubMed ID: 481658
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Serum middle molecules in uremia.
    Buzio C; Manari A; Calderini C; Montagna G; Migone L
    Artif Organs; 1981; 4 Suppl():143-50. PubMed ID: 7295081
    [No Abstract]   [Full Text] [Related]  

  • 33. Treatment of uremic anemia with recombinant erythropoietin also reduces the defects in platelet adhesion and aggregation caused by uremic plasma.
    Zwaginga JJ; IJsseldijk MJ; de Groot PG; Kooistra M; Vos J; van Es A; Koomans HA; Struyvenberg A; Sixma JJ
    Thromb Haemost; 1991 Dec; 66(6):638-47. PubMed ID: 1665596
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Search for peptidic "middle molecules" in uremic sera: isolation and chemical identification of fibrinogen fragments.
    Kaplan B; Cojocaru M; Unsworth E; Knecht A; Martin BM
    J Chromatogr B Analyt Technol Biomed Life Sci; 2003 Oct; 796(1):141-53. PubMed ID: 14552825
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Ion-pair high-performance liquid chromatography profiling of a uremic toxin fraction.
    Gallice P; Monti JP; Le Gall JM; Crevat A; Murisasco A
    J Chromatogr; 1987 Nov; 422():263-6. PubMed ID: 3437013
    [No Abstract]   [Full Text] [Related]  

  • 36. Effects of azathioprine and mizoribine on aggregation of normal and uremic platelets.
    Malyszko JS; Malyszko J; Pawlak K; Mysliwiec M; Takada Y; Takada A
    Transplant Proc; 1996 Dec; 28(6):3488-9. PubMed ID: 8962356
    [No Abstract]   [Full Text] [Related]  

  • 37. Gel-filtration on psoriasic and uremic serum and dialysis fluid.
    Lamperi S; Buoncristiani U; Carozzi S; Cozzari M; Icardi A; Trasforini D
    Artif Organs; 1981; 4 Suppl():156-9. PubMed ID: 7295083
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Middle molecular weight substances and uremic polyneuropathy.
    Dukanović L; Petrović J; Potić J
    Acta Med Iugosl; 1990; 44(2):117-28. PubMed ID: 2162129
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Evaluation of blood toxicity in chronic uremia by an improved chromatographic method.
    Politi L; D'Angelo AR; Caramia M; Molinaro M; Nicoletti R; Cerulli N; Moriggi M; Scandurra R
    Clin Exp Dial Apheresis; 1981; 5(3):277-84. PubMed ID: 7333038
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Preparative isolation of middle molecular weight fractions from the hemofiltrate of patients with chronic uremia.
    Brunner H; Mann H; Essers U; Schultheis R; Byrne T; Heintz R
    Artif Organs; 1978 Nov; 2(4):375-7. PubMed ID: 743009
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.